Tag Archives: GVHD

October, 2018

June, 2018

January, 2018

January, 2017

December, 2016

June, 2016

  • 24 June

    FDA Grants Breakthrough Therapy Designation to Incyte’s Jakafi for GVHD

    WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ruxolitinib (Jakafi®) for the treatment of patients with acute graft-versus-host disease (GVHD). There are currently no approved treatments for patients with acute GVHD. Breakthrough Therapy Designation is designed …